Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 5

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 5
---
 the skin acts as a continuous glucose monitor
(CGM) for several months. The ability of Lumee™ Glucose to provide continuous glucose monitoring with only an initial single
injection, is an attractive alternative for people with diabetes to manage their disease without the need for frequent finger sticks
required by standard glucometers, or the need for weekly sensor replacement as required by current short-term needle-type CGMs.

<div align='center'>1</div>

The Committed Equity Facility

On July 28, 2025, we entered into the Purchase
Agreement and a related registration rights agreement (the “ELOC Registration Rights Agreement”), with Ascent. Pursuant to
the terms and conditions set forth in the Purchase Agreement, we may, from time to time and at our discretion, issue and sell to Ascent
shares of its common stock (the “Purchased Securities”) for an aggregate purchase price of up to $100,000,000 (the “Maximum
Aggregate Purchase Price”), subject to certain limitations and conditions.

Under the Purchase Agreement, we may deliver advance
notices (each, an “Advance Notice”) to the Purchaser to request the purchase of shares of common stock, with each closing
(a “Closing”) to occur on a trading day following the end of a 10 or fewer trading day valuation period commencing
on the trading date immediately following the delivery of the Advance Notice, or as determined by the Purchaser. The purchase price per
share at each Closing will be equal to 97% of the lowest volume-weighted average price (“VWAP”) of the Company’s
common stock during the applicable valuation period, subject to a floor price and other adjustments as set forth in the Purchase Agreement.
The maximum purchase price at any single Closing is limited to the lower of (a) $5,000,000 or (b) 100% of the average daily
traded value of the common stock for the five trading days immediately preceding such Closing.

The Purchase Agreement contains certain limitations,
including that the aggregate number of shares issued under the Purchase Agreement may not exceed the number of shares registered under
the applicable registration statement or the exchange cap (generally 19.9% of the Company’s outstanding common stock as of the effective
date), unless stockholder approval is obtained or as otherwise permitted by the rules of the principal trading market. In addition, the
Purchaser’s beneficial ownership of the Company’s common stock is limited to 9.99% of the outstanding shares